Cargando…
Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
Connective tissue growth factor (CCN2) is a major pro-fibrotic factor that frequently acts downstream of transforming growth factor beta (TGF-β)-mediated fibrogenic pathways. Much of our knowledge of CCN2 in fibrosis has come from studies in which its production or activity have been experimentally...
Autor principal: | Brigstock, David R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686750/ https://www.ncbi.nlm.nih.gov/pubmed/19294531 http://dx.doi.org/10.1007/s12079-009-0043-9 |
Ejemplares similares
-
Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals
por: Brigstock, David R.
Publicado: (2009) -
Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor (CCN2)
por: Huang, Guangcun, et al.
Publicado: (2011) -
Activation of nuclear factor kappa B (NF-κB) by connective tissue growth factor (CCN2) is involved in sustaining the survival of primary rat hepatic stellate cells
por: Gao, Runping, et al.
Publicado: (2005) -
Attenuation of fibrosis in vitro and in vivo with SPARC siRNA
por: Wang, Jiu-Cun, et al.
Publicado: (2010) -
Tracking in vitro and in vivo siRNA electrotransfer in tumor cells
por: Paganin-Gioanni, Aurelie, et al.
Publicado: (2008)